News

Catalent And Valerion Therapeutics Collaborate To Bring New Treatments For Orphan Genetic Disorders To Market

Somerset, N.J. – December 2, 2014 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it is to collaborate with Valerion Therapeutics, LLC, an emerging science-driven company, focused on the development of bio-therapeutics for orphan genetic diseases, to develop […]READ MORE...

MTM: MDA Funds Development of Myotubularin-Based Treatment

Valerion Therapeutics (formerly 4s3 Bioscience), with support from MDA, will continue testing its experimental myotubularin-based compound in mice and will begin producing a pharmaceutical-grade compound. The compound, 3E10FV-MTM1, has shown benefit in myotubularin-deficient mice with a disorder mimicking human MTM.READ MORE...

4s3 Bioscience, Inc. Secures $20M in Series A Financing

March 5, 2012. 4s3 Bioscience, Inc. Secures $20M in Series A Financing 4s3 Bioscience, Inc. (4s3), a privately­‐held biotherapeutics company focused on developing genetic disease therapies for orphan neuromuscular disorders announced today the closing of a $20 million Series A financing with KLP Enterprises, LLC (KLP). Read the full release as a pdf.READ MORE...